네트워크 R&D: 비용 효율적인 R&D가 최초의 개발을 가능하게 함
프로젝트 관리에 기반한 오픈 혁신
Qurient는 ‘자본 효율적인 혁신’을 달성하기 위해 고유한 연구 및 개발 모델 인 ‘네트워크 R&D’ 모델을 소개했습니다.
‘네트워크 R&D’ 모델은 최소한의 핵심 연구 능력을 내부에 유지하면서 필요에 따라 연구 및 개발 네트워크를 외부로 확보하는 데 중점을 둡니다. 네트워크 R&D는 내부 및 외부 연구가 힘을 모아 새로운 약 개발의 공통 목표를 달성하기 위해 리스크를 공유하는 오픈 혁신을 촉진합니다.
Qurient는 평균 20명 미만의 직원으로 창립 이후 두 가지 의약품 후보물질을 세계적인 임상 개발 단계로 이끌었으며, 성공적으로 세 가지 전임상 프로그램을 운영했습니다. 이 탁월한 성과는 자본 효율적인 혁신이 어떻게 가능한지를 명백히 보여줍니다.

의료 분야에서 충족되지 않은 필요에 대한 혁신
Qurient의 미션은 전 세계의 환자들을 돕기 위해 의료 분야에서 충족되지 않은 필요에 대한 혁신을 제공하는 것입니다. 이 미션을 수행함으로써 Qurient는 주주들을 위한 구체적인 가치를 창출할 수 있을 것입니다.

Adrixetinib(Q702), Q901, Q301, Telacebec(Q203)

2023
Exclusive License Agreement with TB Alliance to develop and commercialize Telacebec(Q203)02.03
Designated as “Korea Innovative Pharmaceutical Company” (Ministry of Health and Welfare)01.19
2022
Collaboration Agreement with MSD to Evaluate Selective CDK7 Inhibitor Q901 in Combination With KEYTRUDA®09.14
MFDS approval for Q702 phase 1b/2 study in Combination With KEYTRUDA®09.06
US FDA IND filing for Q702 phase 1b/2 study in Combination With KEYTRUDA®02.16
Telacebec(Q203), voluntarily suspend of COVID-19 phase 2 study in public of South Africa02.11
Q901, US FDA approval for phase 1/2 study02.08
2021
Capital raise of 5 million EUR in QLi5 Therapeutics(Subsidiary)12.22
Capital raise of 12.5 billion KRW12.17
Collaboration Agreement with MSD to Evaluate Selective Triple Inhibitor Q702 in Combination With KEYTRUDA®11.23
Q702, Presented by SWOG(Southwest Oncology Group) Fall 2021 Meeting10.14
Posted 2021 AACR annual meeting(Q901)04.12
Q702, Initiation of clinical patient dosing for phase 1/2 study in US01.26
FDA grants orphan drug designation to Qurient’s Buruli ulcer treatment(Telacebec)01.14
2020
Telacebec(Q203), approval for COVID-19 phase 2 study in Republic of South Africa11.24
Capital raise of 60 billion KRW10.29
Telacebec(Q203), IND filing of COVID-19 phase 2 study in Republic of South Africa10.13
Telacebec(Q203), Signed a Material Transfer Agreement with Janssen09.24
Posted 2020 AACR annual meeting (Q702 / Q901)06.23
Q301, Completion of phase 2b study05.28
Q702, US FDA approval for Immuno-oncology therapy phase 1 study05.23
Published in New England Journal of Medicine(NEJM) to result of Telacebec(Q203) phase 2a study03.26
Establishment of subsidiary "QLi5 Therapeutics GmbH" in Germany01.16
2019
Telacebec(Q203), Completion of Tuberculosis phase 2a study12.17
Posted 2019 AACR annual meeting in Atlanta (Q702)04.02
Q301 Phase 2a Results presented at 2019 American Academy of Dermatology Annual Meeting in Washington DC03.02
2018
Telacebec (Q203) U.S. FDA Fast Track Designation11.12
Capital raise of 40 billion KRW10.19
Received grant from Korea Drug Development Fund for Telacebec (Q203) Phase 2a study10.01
US FDA approval for Telacebec (Q203) phase 2a study07.16
US FDA approval for Q301 phase 2b study06.21
Completion of TB Telacebec (Q203) phase 1b study05.05
Confirmation of “Telacebec ” as a generic name for Q203 by INN & USAN03.01
2017
South Africa MCC approval for Q203 phase 2a study12.20
Posted 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (Q701 & Q702 / Q901 )10.26
Published in European Journal of Medicinal Chemistry. 136 (2017);420-427 (Title : Synthesis and structure-activity relationships of novel fused ring analogues of Q203 as antitubercular agents)08.18
EDCTP(European & Developing Countries Clinical Trials Partnership) grant awarded to PanACEA consortium to run Q203 clinical studies02.28
Published in European Journal of Medicinal Chemistry. 125 (2017);807-815 (Title : Synthesis and structure-activity studies of side chain analogues of the anti-tubercular agent, Q203)01.05
2016
US FDA approval for Q203 Phase 1b study08.29
Completion of Q301 phase 2a study05.19
Initial public offering on Korea Exchange (KRX:115180)02.29
2015
Q203 U.S. FDA Orphan Drug Designation12.28
Received grant from Korea Drug Development Fund for Q203 phase 1 study12.16
US FDA IND approval for Q203 phase 1 study07.23
US FDA approval for Q301 phase 2a study03.12
In-licensed CDK7 inhibitor program from Max Planck Innovation / Lead Discovery Center02.27
Umbrella partnership agreement signed with Max Planck Innovation / Lead Discovery Center02.06
2014
Capital raise of 15.5 billion KRW06.09
Published in Journal of Medicinal Chemistry. 57(12);5293–5305 (Title : Lead Optimization of a Novel Series of Imidazo[1,2-a]pyridine Amides Leading to a Clinical Candidate (Q203) as a Multi- and Extensively-Drug-Resistant Anti-tuberculosis Agent)05.28
Russia and CIS rights for Q203 licensed to Infectex (a subsidiary company of Maxwell Biotech Group, Russia)01.21
2013
Published in Nature medicine. 19(9);1157-60. (Title : Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis)08.04
Capital raise of 3 billion KRW05.10
Received grant from Korea Drug Development Fund for Q203 preclinical IND enabling studies04.30
In-licensed Axl inhibitor program from Max Planck Innovation / Lead Discovery Center02.21
2012
Capital raise of 3 billion KRW09.19
2011
Company name change to “Qurient Co., Ltd”10.21
Capital raise of 1 million USD02.09
2010
Won Gate II competition for 1M USD investment by Novartis Venture Fund09.02
In-licensed anti-tuberculosis antibiotics programs from Institut Pasteur Korea03.04
2009
Series A finance of 4 billion KRW11.20
2008
Foundation of Qurient (formerly Quro Science Co. Ltd.)